Our company announced that it signed a sales and distribution contract for Pristiq Extended-Release Tablet (Desvenlafaxine succinate monohydrate), which is an SNRI (Serotonin-Noradrenaline Reuptake Inhibitor)-type antidepressant by Pfizer Pharmaceuticals Korea (CEO & President Oh Dongwook) for all domestic channels by extending the promotion contract on December 7th.

The two companies have decided to renew the sales and distribution contract for Pristiq Extended-Release Tablets based on the successful partnership over the past five years. Our company and Pfizer Pharmaceuticals Korea have been cooperating since 2018 by signing a co-promotion contract for the sale and distribution of Pristiq Extended-Release Tablets in hospitals and clinics.

According to this agreement, Pfizer Pharmaceuticals Korea will continue to lead the importation and marketing of the product, and our company will expand the scope of co-promotion, which was previously conducted for hospitals and clinics, to sales and distribution in all domestic channels.

President Yoo Junha said, “The contract could be renewed based on the trust that both companies have built over the past seven years. Dong Wha Pharm will strive to provide better treatment opportunities to customers by further strengthening its expertise in the CNS field.”

Director Chung Janghwan of the Internal Medicine Division at Pfizer Pharmaceuticals Korea said, “We hope that this agreement with Dong Wha Pharm will provide more patients suffering from major depression with Pfizer’s innovative treatment options, and Pfizer will continue to realize the corporate value of ‘Breakthroughs that Change Patients’ Lives.’”

Pristiq Extended-Released Tablet is an antidepressant made from desvenlafaxine, the main active metabolite of venlafaxine, and is not metabolized or inhibited by CYP2D6. It is an SNRI antidepressant with a low risk of drug interaction.